Clinical efficacy and safety of treatments for pancreatic and extra-pancreatic neuroendocrine tumours following treatment failure or disease progression: A systematic literature review

#4581

Introduction: Neuroendocrine tumours (NETs) are a diverse group of rare malignancies with few effective targeted treatments, highlighting a need for novel therapies.

Aim(s): To identify clinical efficacy and safety data for patients with pancreatic (pNETs) or extra-pancreatic (epNETs) NETs who have experienced treatment failure or disease progression (PD) following previous therapeutic interventions.

Materials and methods: In May 2024, 5 electronic databases were searched, in addition to grey literature sources. Eligible studies reported clinical efficacy or safety data for adults with advanced NETs, provided ≥70% of patients experienced treatment failure or PD following: everolimus, sunitinib, 177Lu-dotatate, CAPTEM, STZ/5-FU, FOLFOX, or IFN-∝.

Conference:

Presenting Author:

Authors: Karim E, Srirajaskanthan R, Bensegnor H, Chan K, Drane E,

Keywords: Neuroendocrine tumour, Systematic literature review,